| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
interferon alpha 1 | 0.371 | 0.923 |
|
group | 0.100 | None | 0.958 | 48 | 0 | 1999 | 2020 | |||||||||
|
interferon alpha 13 | 0.374 | 0.923 |
|
group | 0.100 | None | 0.958 | 48 | 0 | 1999 | 2020 | |||||||||
|
T cell receptor beta variable 20/OR9-2 (non-functional) | 0.403 | 0.923 |
|
group | 0.100 | None | 1.000 | 46 | 0 | 1990 | 2019 | |||||||||
|
Hashimoto thyroiditis | 0.505 | 0.731 |
|
group | 0.100 | None | 0.960 | 25 | 0 | 2000 | 2020 | |||||||||
|
microRNA 146a | 0.398 | 0.885 |
|
group | 0.100 | None | 0.867 | 15 | 1 | 2010 | 2018 | |||||||||
|
long intergenic non-protein coding RNA 2605 | 0.490 | 0.769 |
|
group | 0.100 | None | 1.000 | 14 | 0 | 2006 | 2018 | |||||||||
|
KLRC4-KLRK1 readthrough | 0.469 | 0.769 |
|
group | 0.100 | None | 0.923 | 13 | 0 | 2004 | 2018 | |||||||||
|
microRNA 155 | 0.384 | 0.885 |
|
group | 0.100 | None | 1.000 | 12 | 0 | 2011 | 2019 | |||||||||
|
CD24 molecule | 0.472 | 0.769 |
|
group | 0.090 | None | 1.000 | 9 | 1 | 2007 | 2018 | |||||||||
|
small ubiquitin like modifier 4 | 0.653 | 0.577 |
|
group | 0.090 | None | 1.000 | 9 | 1 | 2000 | 2012 | |||||||||
|
interferon beta 1 | 0.421 | 0.846 |
|
group | 0.080 | None | 1.000 | 8 | 0 | 1996 | 2019 | |||||||||
|
interferon, type 1, cluster | 0.565 | 0.731 |
|
group | 0.070 | None | 1.000 | 7 | 0 | 2009 | 2019 | |||||||||
|
long intergenic non-protein coding RNA 1193 | 0.565 | 0.692 |
|
group | 0.070 | None | 1.000 | 7 | 0 | 2003 | 2011 | |||||||||
|
Cerebellar degeneration-related autoantigen-3 | 0.472 | 0.808 |
|
group | 0.070 | None | 1.000 | 7 | 0 | 1998 | 2017 | |||||||||
|
Cbl proto-oncogene like 2 | 0.476 | 0.808 |
|
group | 0.060 | None | 1.000 | 6 | 0 | 2008 | 2019 | |||||||||
|
microRNA 21 | 0.363 | 0.846 |
|
group | 0.060 | None | 1.000 | 6 | 0 | 2016 | 2019 | |||||||||
|
Myeloproliferative syndrome, transient (transient abnormal | 0.528 | 0.731 |
|
group | 0.060 | None | 1.000 | 6 | 0 | 2017 | 2019 | |||||||||
|
MAS related GPR family member X3 | 0.529 | 0.923 |
|
group | 0.050 | None | 1.000 | 5 | 0 | 2017 | 2019 | |||||||||
|
MAS related GPR family member X4 | 0.531 | 0.923 |
|
group | 0.050 | None | 1.000 | 5 | 0 | 2017 | 2019 | |||||||||
|
MAS related GPR family member X1 | 0.531 | 0.923 |
|
group | 0.050 | None | 1.000 | 5 | 0 | 2017 | 2019 | |||||||||
|
long intergenic non-protein coding RNA 1194 | 0.470 | 0.769 |
|
group | 0.050 | None | 1.000 | 5 | 0 | 2006 | 2017 | |||||||||
|
miR-17-92a-1 cluster host gene | 0.483 | 0.808 |
|
group | 0.050 | None | 1.000 | 5 | 0 | 2008 | 2019 | |||||||||
|
multiple sclerosis | 0.599 | 0.692 |
|
group | 0.050 | None | 1.000 | 5 | 0 | 2010 | 2019 | |||||||||
|
vomeronasal 1 receptor 17 pseudogene | 0.529 | 0.923 |
|
group | 0.050 | None | 1.000 | 5 | 0 | 2017 | 2019 | |||||||||
|
G protein-coupled receptor 166 pseudogene | 0.531 | 0.923 |
|
group | 0.050 | None | 1.000 | 5 | 0 | 2017 | 2019 |